Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5398_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •Contributors
- •1. Introduction
- •2. The Initial Phase of Drug Delivery Systems
- •3. Recent Drug Delivery Systems
- •4. Drug Delivery via Carriers
- •5.4 Polymer-Lipid Hybrid Nanoparticles Drug Delivery System
- •5.5 Self-Micro Emulsifying Drug Delivery System
- •5.6 In Situ Gel Drug Delivery System
- •5.8 Targeted Drug Delivery
- •6. Ceramic-Based Drug Delivery System
- •7. Polysaccharide-Based Drug Delivery System
- •8. Closed Loop Insulin Delivery System
- •9. Liposome-Mediated Drug Delivery
- •5. Recent Drug Delivery Systems
- •5.3 Hexagonal Boron Nitride Nanosheet Drug Delivery System
- •10. Dendrimers
- •11. PEGylated Drug Delivery System
- •12. Antibody-Drug Conjugate System
- •13. Mesoporous Silica-Based Drug Delivery
- •14. Transdermal Drug Delivery System
- •15. Hydrogel-Mediated Ocular Drug Delivery
- •16. Challenges with Current Drug Delivery Systems
- •17. Future Direction and Conclusion
- •References
- •1. Introduction
- •2. Pharmacokinetic Principles
- •2.1 Application of the Pharmacokinetic Principle in the Biomedical Fields
- •3. Cell Membrane/Biological Membrane
- •3.1 Passage of Drugs Across Biological Membranes
- •3.1.1 Simple Transport
- •3.1.2 Specialized Transport
- •4. Routes of Drug Administration
- •4.1 Oral (Enteral) Versus Parenteral Administration
- •4.2 Various Routes of Drug Administration
- •5. Absorption
- •5.1 Factors Affecting Absorption of Drugs
- •5.1.1 Physio-chemical Characteristics
- •5.1.2 Dosage Form
- •5.1.3 Concentration and Volume
- •5.1.4 Blood Flow
- •5.1.5 Surface Area
- •5.1.6 Administration Route
- •5.1.7 Disease States
- •5.2 Gastrointestinal Tract
- •5.3 Parenteral Sites
- •5.4 Pulmonary Sites (Alveoli)
- •5.5 Topical Sites
- •6. Distribution
- •6.1 Factors Affecting Distribution of Drugs
- •6.1.1 Physicochemical Properties of the Drug
- •6.1.2 Binding to Plasma and Tissue Proteins
- •6.1.3 Blood Flow and Organ Size
- •6.1.4 Specialized Compartments and Barriers
- •6.1.5 Specialized Transport Systems
- •6.1.6 Disease States
- •6.1.7 Physiological Factors
- •7. Metabolism/Biotransformation
- •7.1 Functions of Metabolism
- •7.2 Sites of Metabolism
- •7.3.1 Microsomal Enzymes
- •7.3.2 Non-microsomal Enzymes
- •7.4 Pathways of Biotransformation
- •8. Excretion
- •8.1 Routes of Excretion
- •8.1.1 Renal Excretion of Drugs
- •8.1.2 Extra-Renal Excretion of Drugs
- •9.1 Minimum Effective Concentration (MEC)
- •9.2 Maximum Safe Concentration (MSC) or Minimum Toxic Concentration (MTC)
- •9.4 Area Under the Curve (AUC)
- •9.5 Peak Effect
- •9.7 Onset of Action
- •9.8 Onset Time
- •9.9 Duration of Action
- •10. Order of Pharmacokinetic Processes
- •10.1 Zero-Order Kinetics
- •10.2 First-Order Kinetics
- •10.3 Mixed-Order Kinetics
- •11. Pharmacokinetic Models
- •11.1 Compartmental Models
- •11.3 Physiological Models
- •12. Determinants of Pharmacokinetics
- •12.1 Absorption
- •12.1.1 Bioavailability
- •12.1.2 Bioequivalence
- •12.1.3 Area Under Curve (AUC)
- •12.2 Distribution
- •12.2.1 Volume of Distribution
- •12.3 Elimination
- •12.3.2 Clearance (Cl) or Body Clearance
- •13. Conclusion
- •References
- •1. Introduction
- •2. Principles of Targeted Drug Delivery
- •3.1 Changes in pH and Salt Development
- •3.7 Dendrimers
- •4.1 Small-Sized Molecule-Based Targeting Strategies
- •4.2 Nucleic Acid Fragment-Based Targeting Strategies
- •4.3 Peptide- and Antibody-Based Targeting Strategies
- •4.4 Cell-Based Targeting Strategies
- •5. Conclusion
- •References
- •3.4 Liposomes
- •3.5 Solid Lipid Nanoparticles
- •3.6 Co-crystal Preparation
- •1. Introduction
- •2. History
- •3.1 Organic Nanoparticles
- •3.2 Inorganic Nanoparticles
- •4. Nanotechnology-Based Drug Delivery Systems
- •4.1 Smart Drug Delivery Systems
- •4.3 Multifunctional Drug Carriers
- •4.4 Organic/Inorganic Composites
- •5. Nanoparticulate Drug Delivery Systems
- •5.1 Liposomes
- •5.2 Microemulsions
- •5.3 Nanoparticles
- •6. Applications
- •6.1 Enhanced Drug Delivery
- •6.2 Overcoming Biological Barriers
- •6.3 Controlled Drug Release
- •6.4 Combination Therapy
- •6.5 Personalized Medicine
- •7. Limitations
- •7.1 Complexity and Cost
- •7.2 Biocompatibility and Toxicity
- •7.3 Stability and Shelf Life
- •7.4 Drug Loading and Release
- •7.5 Biological Barriers and Clearance
- •8. Conclusions
- •References
- •1. Introduction
- •2. Guidelines for Design of Lipid-Based Formulations
- •3. Formulation Strategies
- •3.1 Lipid Nanoparticles
- •3.1.1 Solid Lipid Nanoparticles (SLNs)
- •3.1.2 Nanostructured Lipid Carriers (NLCs)
- •3.2 Liposomes
- •3.2.1 Conventional Liposomes
- •3.2.2 PEGylated Liposomes
- •3.2.3 Multifunctional Liposomes
- •3.3 Microemulsions and Self-micro Emulsifying Drug Delivery Systems (SMEDDS)
- •3.4 Hybrid Systems
- •3.4.1 Lipid-Polymer Hybrid Nanoparticles
- •3.4.2 Lipid-Protein Hybrid Systems
- •4. Advanced Characterization Methods
- •4.1 In Vitro and In Vivo Assessment
- •4.1.1 Dissolution Studies
- •4.1.2 Permeability Studies
- •4.2 Imaging Techniques
- •4.2.1 Electron Microscopy
- •4.2.2 Fluorescence Imaging
- •Fluorescent Probes
- •Confocal Microscopy
- •4.2.3 Magnetic Resonance Imaging (MRI)
- •4.3 Stability Studies
- •4.3.1 Oxidative Stability
- •4.3.2 Thermal Stability
- •5. Applications of Lipid-Based Drug Delivery Systems
- •5.1 Cancer Therapy
- •5.1.1 Targeted Drug Delivery
- •5.1.2 Combination Therapy
- •5.2 Central Nervous System Disorders
- •5.2.2 Neuroprotective Effects
- •5.3 Antiviral and Antimicrobial Applications
- •5.3.1 Lipid Nanoparticles for Antiviral Drugs
- •5.3.2 Antibiotic Delivery Systems
- •6. Future Perspectives and Challenges
- •7. Conclusion
- •References
- •1. Introduction
- •3. Design and Characterization of Polymeric Drug Delivery Systems
- •4. Responsive Polymers
- •4.1 Polymeric Hydrogels
- •4.1.1 Characterization of Polymeric Hydrogels
- •Structural Analysis
- •Functional Analysis
- •4.2 Polymeric Micelles
- •4.2.1 Characterization of Polymeric Micelle
- •Critical Micelle Concentration Determination (CMC)
- •Morphological Characterization
- •Physicochemical Characterization
- •4.3 Liposomes
- •4.3.1 Ethosome
- •4.3.2 Transferosome
- •4.3.3 Niosome
- •4.4 Polyplexes or Polymer-Drug Conjugates
- •4.4.1 Dendrimers
- •4.4.2 Polymer-Protein Conjugates
- •4.4.3 Polymeric Nanoparticles
- •5. Conclusion
- •6. Future Prospects
- •References
- •1. Introduction
- •2.1 Types of Stimuli
- •3. Mechanism of Stimuli Responsiveness
- •3.1 pH-Responsive Systems
- •4. Materials
- •4.1 pH-Responsive Materials
- •4.4 Synthetic Thermo-Responsive Materials
- •4.7 Magnetic Responsive Materials
- •4.8.1 Intrinsically Conducting Polymers
- •4.8.2 Hydrogels
- •5. Methods
- •5.1 pH-Responsive Drug Delivery Systems
- •6. Conclusion
- •7. Notes
- •References
- •1. Introduction
- •3. Basic Features Required for the Biomaterial
- •4. Characteristics of Biomaterials
- •6. Biocompatibility as the Crucial Item
- •7. Biomaterials in Drug Delivery
- •8. Controlled Drug Delivery
- •9. Clinical Need for Controlled Drug Delivery
- •10. Biomaterials for Controlled Release of Small Molecules
- •11. Bioresponsive Polymers: From Design to Implementation
- •11.3 Hydrolysis and Enzymatically Responsive Polymers
- •11.7 Swelling and Contracting Polymers
- •12. Transdermal Drug Delivery Systems
- •12.1 Barriers to Transdermal Delivery
- •12.2 Development of Transdermal Drug Delivery Patches
- •12.3 Hydrogels Versus Non-hydrogel Polymeric Patches
- •12.4 Patches Based on Biopolymers
- •12.5 Patches Based on Synthetic Polymers
- •12.6 Drug Particles/Carriers
- •12.7 Commercial Patches
- •13. Smart Biomaterials
- •14. Conclusion and Future Perspective
- •References
- •1. Introduction
- •1.1 Historical Evolution
- •2. Skin Anatomy and Physiology
- •2.1 Cutaneous Layer Organization
- •2.2 Cutaneous Barrier Function
- •3. Mechanisms of Transdermal Drug Delivery
- •4. Formulation Strategies for Transdermal Drug Delivery
- •4.1 Drug Selection Criteria
- •4.2 Vehicle and Excipient Considerations
- •4.3 Permeation Enhancers
- •4.4 Transdermal Drug Delivery Technologies
- •5. Evaluation Methods for Transdermal Drug Delivery Systems
- •6. Applications of Transdermal Drug Delivery
- •6.1 Therapeutic Areas
- •6.2 Case Studies of Successful Transdermal Products
- •7. Regulatory Considerations and Approval Process
- •7.1 FDA Guidelines for Transdermal Drug Delivery Systems
- •7.2 Quality Control and Manufacturing Standards
- •7.3 Clinical Trial Requirements
- •8. Challenges and Future Perspectives
- •8.1 Overcoming Cutaneous Barrier Properties
- •8.2 Expanding the Range of Deliverable Drugs
- •8.3 Intelligent and Responsive Transdermal Systems
- •8.4 Integration with Other Drug Delivery Technologies
- •8.5 Conclusion
- •References
- •1. Background
- •2. Importance of the Tumor Microenvironment (TME) in Cancer Progression and Therapy
- •2.1 Components of the TME
- •2.2 Therapeutic Targeting of the TME
- •2.3 Impact of Standard Therapies on the TME
- •3. Tumor-Homing Peptides
- •3.1 Different Strategies for Targeting Peptides to Tumor Microenvironment
- •3.2 Applications and Development
- •3.3 Examples and Discoveries
- •4. Tumor Microenvironment Responsive Drug Delivery Systems (DDSS)
- •5. Nanoparticle-Based Smart Drug Delivery Systems
- •5.1.1 Endogenous Stimulus-Responsive Drug Delivery Systems (DDSs)
- •5.1.2 Exogenous Stimulus-Responsive DDSs
- •5.2.2 Dynamic Strategies for Tumor Targeting
- •6. Challenges and Opportunities for Targeted Delivery to Cancer Cells
- •7. Future Directions
- •8. Conclusions
- •References
- •1. Introduction
- •2. Materials
- •2.1 Types of Biosensors
- •2.1.2 Smart Polymers
- •2.1.3 Microfabricated Devices
- •2.2.1 Enzyme-Based Biosensors
- •2.2.2 Antibody-Based Biosensors
- •2.2.3 Aptamer-Based Biosensors
- •2.2.4 Whole-Cell-Based Biosensors
- •3. Methods
- •3.1 Approach Toward Designing Biosensors
- •3.1.1 Selection of the Analyte and Bioreceptors
- •3.1.2 Immobilization of Biosensors
- •3.1.3 Selection of Transducer
- •3.2 Green Biosensors
- •3.3 Challenges in Development of Biosensors-Based Drug Delivery Systems
- •References
- •1. Introduction
- •3. Ocular Barriers Hindering Absorption of Drugs
- •3.1 Precorneal Barriers
- •3.1.1 Tear Film, Tear Turnover, and Nasolacrimal Duct Drainage
- •3.1.3 Conjunctival and Scleral Barriers
- •3.2 Corneal Barrier
- •3.3 Blood-Ocular Barriers
- •4. Various Routes for Ocular Drug Delivery
- •4.1 Topical Administration
- •4.2 Subconjunctival Administration
- •4.3 Transscleral Administration
- •4.4 Intracameral Administration
- •4.5 Intravitreal Injections/Implants (IVIs)
- •4.6 Retrobulbar Administration
- •4.7 Systemic Administration
- •5. Nanotechnology-Based Ocular Drug Delivery Platforms
- •5.1 Nanoparticles (NPs)
- •5.1.1 Polymeric Nanoparticles (PNPs)
- •5.2 Nanomicelles
- •5.3 Nanoemulsions (NEs)
- •5.4 Nanosuspensions
- •5.5 Nanocrystals (NCs)
- •5.6 Liposomes
- •5.7 Microemulsions
- •5.8 Niosomes
- •5.10 Dendrimers
- •5.11 Nanowafers
- •5.12 Cubosomes
- •5.13 Bilosomes
- •5.14 Olaminosomes
- •5.15 Contact Lenses
- •5.16 Hydrogels
- •5.17 Microneedles (MNs)
- •6. Alternative Ocular Drug Delivery Approaches
- •6.1 Gene Therapy
- •6.1.1 Viral Vectors
- •6.1.2 Non-viral Vectors
- •6.1.3 Antisense Oligonucleotides (ASOs), RNAi, CRISPR-Cas9
- •6.2 Exosomes
- •6.3 Self-nano Emulsifying Drug Delivery Structures (SNEDDS)
- •7. Clinical Status of Nanotechnology-Based Ocular Drug Delivery Systems
- •8. Future Outlooks
- •References
- •1. Introduction
- •2. Anatomy and Physiology of GIT
- •2.1 Mouth and Esophagus
- •2.2 Stomach
- •2.3 Small Intestine
- •2.4 Ruminant Digestive System
- •3. Blood Supply
- •4. Nerve Supply
- •5. Challenges in GIT Drug Delivery
- •5.1 Acidic Environment of the Stomach
- •5.2 Alkaline pH of the Intestine
- •5.3 Variable GI Transit Times
- •6. Future Opportunities in GIT Drug Delivery
- •6.1.1 Targeted Delivery Systems
- •6.1.2 Ligand-Conjugated Nanoparticles
- •6.1.3 Liposomes
- •6.1.4 Solid Lipid Nanoparticles
- •6.2 Controlled Release Systems
- •6.2.1 Osmotic Pumps
- •6.2.2 Matrix Systems
- •6.3 Mucoadhesive Systems
- •6.3.1 Mucoadhesive Polymers
- •6.4 Absorption Enhancers
- •6.5 Tight Junction Modulators
- •6.6 Development of Prodrugs
- •7. Conclusion
- •References
- •1. Introduction
- •2. Anatomy and Physiology of the Respiratory System
- •3. Traditional Methods of Respiratory Drug Delivery
- •3.1 Metered-Dose Inhalers (MDIs)
- •3.2 Dry Powder Inhalers (DPIs)
- •3.3 Nebulizers
- •3.5 Improved Patient Compliance Through User-Friendly Devices
- •3.8 Enhanced Absorption by Overcoming Biological Barriers
- •3.9 Macromolecule Delivery Facilitation
- •3.10 Reduced Side Effects Through Improved Targeting
- •3.11 Formulation Challenges Addressed
- •3.12 Smart Technology Integration for Personalized Treatment
- •3.13 Environmental Sustainability Considerations
- •4. Novel Drug Delivery Approaches
- •4.2 Liposomal Formulations
- •5. Advanced Inhalation Devices
- •6. Targeted Drug Delivery Strategies
- •6.2 pH-Responsive Drug Release
- •7. Emerging Therapeutics for Respiratory Diseases
- •8.2 Combination Therapies
- •8.3 Prodrug Approaches
- •9. Personalized Medicine in Respiratory Drug Delivery
- •10. Future Perspectives and Emerging Technologies
- •10.1 3D-Printed Inhalers
- •11. Conclusion
- •References
- •1. Introduction
- •2. Delivery of Small Molecules
- •3. Drawbacks of Conventional Drug Delivery System
- •4. Factors Affecting Cardiovascular Drug Targeting System
- •4.1 Particle Shape
- •4.2 Particle Size
- •4.3 Particle Density
- •4.4 Flow Characteristics
- •5. Various Targeted Drug Delivery Systems
- •5.1 Application of Exosomes and EVs (Extracellular Vesicles)
- •5.4 Nanomedicines in Cardiovascular Therapy
- •5.5 PLGA-Based Nanoparticles
- •5.6 Liposomal Delivery Systems
- •5.7 Delivery of Biologicals
- •5.8 RNA-Based Delivery
- •5.9 Therapeutic Proteins and Peptides
- •6. Future Perspectives and Challenges
- •7. Conclusion
- •References
- •1. Introduction
- •2. Materials
- •2.1 Equipment
- •2.2 Drugs
- •3. Methods
- •3.1.1 Extrusion-Based 3D Bioprinting
- •3.1.2 Inkjet 3D Bioprinting
- •3.1.3 Light-Based Bioprinting
- •3.1.4 Laser-Assisted Printing
- •3.2 Multiple Drug Delivery
- •3.2.1 Multilayer Films with Capsule-Integrated Polypeptide/Polyelectrolyte
- •3.2.2 Multilayer Shells Using Polypeptides/Polyelectrolytes (PL or PG) and LbL Assembly
- •3.3.1 Physical Stimulation-Responsive Drug Delivery Systems
- •3.3.4 Light-Responsive Drug Delivery Systems (LRDDS)
- •3.4 Small Molecule Delivery System
- •3.4.1 Intraarticular Delivery System
- •3.5 Gene Delivery System
- •3.6 Stem Cell Technology
- •4. Conclusion
- •References
- •1. Introduction
- •2. Importance of Targeted Drug Delivery to the Reproductive System
- •3. Challenges in Drug Delivery to the Reproductive System
- •4. Advances in Drug Delivery Systems
- •4.2 Liposomes
- •4.3 Hydrogels and Biodegradable Polymers
- •4.4 Injectable and Implantable Devices
- •4.5 Micro- and Nano-Needles
- •4.6 Spermbots
- •5.1 Vaginal and Cervical Delivery
- •5.2 Uterine and Intrauterine Delivery
- •5.3 Penile and Testicular Delivery
- •6. Targeted and Precision Medicine Approaches
- •6.1 Hormone Replacement Therapy (HRT)
- •6.2 Gene Therapy and RNA-Based Approaches
- •6.3 Personalized Medicine in Reproductive Disorders
- •7. Therapeutic Applications and Innovations
- •7.1 Infertility and Assisted Reproductive Technologies (ART)
- •7.2 Treatment of Reproductive Cancers
- •7.4 Contraceptive Technologies
- •8. Safety and Regulatory Considerations
- •9. Future Directions and Emerging Trends
- •References
- •1. Introduction
- •2. Liposomes
- •3. Preparation of Liposomes
- •3.1 Reagents
- •3.2 Hydration and Liposome Extrusion
- •3.4 Conjugation
- •3.8 PEGylation
- •3.8.1 Materials Required
- •3.8.2 Procedure
- •3.9 Liposomal Doxorubicin (LD)
- •3.10 Marqibo (Vincristine Sulfate)
- •3.11 DepoCyt (Cytarabine)
- •4. Poly(Lactic-co-Glycolic Acid, PLGA) Nanoparticles
- •4.2 Methods
- •4.2.1 Reagents
- •4.2.2 Procedure
- •5. Polycaprolactone (PCL)
- •5.2 pH Sensitivity and Stability
- •5.3 Methods
- •5.3.1 Materials
- •5.4 Drug Loading
- •6. Chitosan-Based Systems
- •6.1 Encapsulation of Nucleic Acids and Proteins
- •6.3 pH Sensitivity and Stability of Chitosan Nanoparticles
- •6.4 Methodology
- •6.4.1 Reagents
- •6.4.2 Procedure
- •7. Dendrimers
- •7.1 Antisense Oligonucleotides
- •7.2 Small-Interfering RNA (siRNA)
- •7.4.1 Divergent Method
- •7.4.2 Convergent Method
- •8. Challenges in Developing Orphan Drugs
- •References
- •1. Introduction
- •2. Vaccine Delivery Systems
- •3. Polymers
- •4. Non-biodegradable NPs
- •5. Calcium Phosphate NPs
- •6. Colloidally Stable Nanoparticles
- •7. Proteasomes
- •8. Liposomes
- •9. Virus-like Particles (VLPs) and Virosomes
- •10. Immune-Stimulating Complexes ISCOMs
- •11. Emulsion Delivery Systems
- •12. Exosome-Based Vaccine Delivery System
- •13. Immunotherapy Using Nano- and Microparticles
- •14. Properties and Role of Nanoparticles in Drug Delivery
- •15. Biomimicry
- •16. Micellar Systems
- •17. Hydrogels
- •18. Edible Vaccines
- •19. Plant-Derived Viruses
- •20. Melt-in Mouth Strips
- •21. Transdermal Delivery
- •22. Delivery of Nucleic Acids
- •23. mRNA Delivery
- •24. Delivery of Cytokines
- •25. DC Targeting
- •26. Drug Delivery Targeting T Cells
- •27. Conclusions
- •References
- •1. Introduction
- •2. Materials
- •2.1 Equipment
- •2.2 Reagents and Solutions
- •3. Methods
- •3.1 Adenovirus
- •3.3 Retroviral Vectors (RV)
- •3.4 Lentivirus (LV)
- •4. Conclusion
- •References
- •1. Introduction
- •2. Technologies Utilizing Cells in Treating Diseases
- •2.1 Somatic Cell Technologies
- •2.2 Immortalized Cell Lines
- •2.5 Genome Editing Technologies
- •2.6 Cell Plasticity Technologies
- •3. Different Kinds of Cells Are Utilized in the Process of Cell Treatment
- •4. The Practices of Regenerative Medicine and Cell Therapy
- •4.1 Veterinary Medicine Therapeutic Uses
- •5. Advancements and Challenges in Drug Delivery
- •6. Drug Delivery Systems and Applications
- •6.2 Drug Nanocarriers Based on Hyaluronic Acid
- •6.3 Hexagonal Boron Nitride Nanosheet Drug Delivery System
- •6.4 Polymer-Lipid Hybrid Nanoparticles
- •6.6 In Situ Gel Drug Delivery System

Polymer-Based Drug Delivery Systems: Design and Characterization 129
40. Borges FTP, Papavasiliou G, Teymour F
(2020) Characterizing the molecular architecture of hydrogels and crosslinked polymer
networks beyond Flory–Rehner—I. Theory.
Biomacromolecules 21:5104–5118
41. Scott RA, Nicholas AP (1999) Highly crosslinked, PEG-containing
tained solute delivery. Biomaterials 20:1371–
1380
42. Tani Y, Yonenuma R, Mori H (2023)
Clusterization-triggered emission of poly
(vinyl amine)-based ampholytic block and
random copolymers. React Funct Polym
184:105518
43. Mahfufah U, Sultan NAF, Fitri AMN,
Elim D, Mahfud MAS, Wafiah N, Friandini
RA, Chabib L, Aliyah; Permana, A.D. (2023)
Application of multipolymers system in the
development of hydrogel-forming microneedle integrated with polyethylene glycol reservoir for transdermal delivery of albendazole.
Eur Polym J 183:111762
44. Xu B, Wang H, Luo Z, Yang J, Wang Z
(2023) Multi-material 3D printing of
mechanochromic double network hydrogels
for on-demand patterning. ACS Appl Mater
Interfaces 15:11122–11130
45. Lin Q, Hu Y, Qiu C, Li X, Sang S, McClements DJ, Chen L, Long J, Xu X, Wang J et al
(2023) Peanut protein-polysaccharide hydrogels based on semi-interpenetrating networks
used for 3D/4D printing. Food Hydrocoll
137:108332
46. Cerritelli S, Velluto D, Hubbell JA (2007)
PEG-SS-PPS: reduction-sensitive disulfide
block copolymer vesicles for intracellular
drug delivery. Biomacromolecules 8:1966–
1972
47. Kolahdoozan M, Rahimi T, Taghizadeh A,
Aghaei H (2023) Preparation of new hydrogels by visible light cross-linking of dextran
methacrylate and poly(ethylene glycol)maleic acid copolymer. Int J Biol Macromol
227:1221–1233
48. Flemming M, Peppas NA (1999) Complexation graft copolymer networks: swelling properties, calcium binding and proteolytic
enzyme inhibition. Biomaterials 20:1701–
1708
49. Xie S, Ren T, Chen G, Zhou Z, Li Z, Wu W,
Huang L (2023) High-performance porous
copolymer hydrogel for oceanic electricity
generation. Chem Eng J 456:140983
50. Baranello MP, Bauer L, Benoit DSW (2014)
Poly(styrene-alt-maleic anhydride)-based
Diblock copolymer micelles exhibit versatile
hydrophobic drug loading, drug-dependent
copolymers for sus-
release, and
resistant ovarian cancer cells. Biomacromolecules 15:2629–2641
51. Jose J, Athira VP, Michel H, Hafeela AR, Bhat
SG, Thomas S, Maria LP (2023) Chapter 1—
Hydrogels: an overview of the history, classification, principles, applications, and
kinetics. In: Thomas S, Sharma B, Jain P, Shekhar S (eds) Sustainable Hydrogels. Elsevier,
Amsterdam, pp 1–22
52. Rahman MS, Islam MM, Islam MS, Zaman A,
Ahmed T, Biswas S, Sharmeen S, Rashid TU,
Rahman MM (2019) Morphological characterization of hydrogels. In: Mondal M
(ed) Cellulose-based superabsorbent hydrogels. Springer, Cham, pp 819–863
53. Fergg F, Keil FJ, Quader H (2001) Investigations of the microscopic structure of poly
(vinyl alcohol) hydrogels by confocal laser
scanning microscopy. Colloid Polym Sci 279:
61–67
54. Abuelfilat AY, Kim Y, Miller P, Hoo SP, Li J,
Chan P, Fu J (2015) Bridging structure and
mechanics of three-dimensional porous
hydrogel with X-ray ultramicroscopy and
atomic force microscopy. RSC Adv 5:63909–
63916
55. Cocarta AI, Hobzova R, Sirc J, Cerna T,
Hrabeta J, Svojgr K, Pochop P, Kodetova M,
Jedelska J, Bakowsky U et al (2019) Hydrogel
implants for transscleral drug delivery for retinoblastoma treatment. Mater Sci Eng C 103:
109799
56. Longchamp A, Kaur K, Macabrey D,
Dubuis C, Corpataux JM, De´glise S, Matson
JB, Allagnat F (2019) Hydrogen sulfidereleasing peptide hydrogel limits the development of intimal hyperplasia in human vein
segments. Acta Biomater 97:374
57. European Medicines Agency (2013) 2 Committee for medicinal products for human use
(CHMP) 3 joint MHLW/EMA reflection
paper on the development of 4 block copolymer micelle medicinal products. European
Medicines Agency, Amsterdam
58. Gao M, Yang Y, Bergfel A, Huang L,
Zheng L, Bowden TM (2020) Self-assembly
of cholesterol end-capped polymer micelles
for controlled drug delivery. J Nanobiotechnol 18:13.
s12951-020-0575-y
59. Scholz N,
Determination of the critical micelle concentration of neutral and ionic surfactants with
Fluorometry, Conductometry, and surface
tension—A method comparison. J Fluoresc
28:465–476
internalization
https://doi.org/10.1186/
Behnke T, Resch-Genger U (2018)
by multidrug

130 Afroz Jahan et al.
60. McKenzie BE, Holder SJ, Sommerdijk NAJM
(2012) Assessing internal structure of polymer assemblies from 2D to 3D CryoTEM:
bicontinuous micelles. Curr Opin Colloid
Interface Sci 17:343–349.
10.1016/j.cocis.2012.09.002
61. Gu PF, Xu H, Sui BW, Gou JX, Meng LK,
62. Puig-Rigall J, Ferna´ndez-Rubio C, Gonza´lez-
63. Negi P, Sharma G, Verma C, Garg P,
64. Jain S, Umamaheshwari RB, Bhadra D, Jain
65. Fang JY, Hwang TL, Leu YL (2003) Effect of
66. Lopez-Pinto JM, Gonza
67. Liu J, Hu G (2007) Advances in studies of
68. Godin B, Touitou E, Rubinstein E,
69. Maghraby GMME, Campbell M, Finnin BC
F, Wang XJ, Qi N, Zhang Y, He HB et al
Sun
(2012) Polymeric micelles based on poly(ethylene glycol) block poly(racemic amino acids)
hybrid polypeptides: conformation-facilitated
drug-loading behavior and potential application as effective anticancer drug carriers. Int J
Nanomedicine 7:109
Benito J, Houston JE, Radulescu A,
Nguewa P, Gonza
Structural characterization by scattering and
spectroscopic methods and biological evaluation of polymeric micelles of Poloxamines and
TPGS as Nanocarriers for Miltefosine delivery. Int J Pharm 578:119057
Rathore C, Kulshrestha S, Lal UR, Gupta B,
Pathania D (2020) Novel Thymoquinone
loaded chitosan-lecithin micelles for effective
wound healing: development, characterization, and preclinical evaluation. Carbohydr
Polym 230:115659
NK (2004) Ethosomes: a novel vesicular carrier for enhanced transdermal delivery of an
anti-HIV agent. Indian J Pharm Sci 66:72–81
enhancers and retarders on percutaneous
absorption of flurbiprofen from hydrogels.
Int J Pharm 250:313–325
Rabasco AM (2005) Effect of cholesterol
and ethanol on dermal delivery from DPPC
liposomes. Int J Pharm 298:1–12
phospholipids as carriers in skin topical application. J Nan Jing Med Univ 21:349–353.
https://doi.org/10.1016/s1007-4376(07)
60076-8
Athamna A, Athamna M (2005) A new
approach for treatment of deep skin infections
by an ethosomal antibiotic preparation: an
in vivo study. J Antimicrob Chemother 55:
989–994
(2005) Mechanisms of action of novel skin
penetration enhancers: phospholipid versus
skin lipid liposomes. Int J Pharm 305:90–104
´
https://doi.org/
lez-Gaitano G (2020)
´
lez-Rodrı´guez ML,
70. Verma DD, Verma S, Blume G, Fahr A (2003)
Liposomes increase skin penetration of
entrapped and non-entrapped hydrophilic
substances into human skin: a skin penetration and confocal laser scanning microscopy
study. Eur J Pharm Biopharm 55:271–277
71. Pandey S, Goyani M, Dev MV, Fakir J (2009)
Transferosomes: a novel approach of transdermal drug. Deliv Sch Res Libr 1:143–150
72. Boinpally RR, Zhou SL, Poondru S,
Devraj G, Jasti BR (2003) Lecithin vesicles
for topical delivery of diclofenac. Eur J
Pharm Biopharm 56:389–392
73. Jain S, Umamaheshwari RB, Bhadra D,
Tripathi P, Jain P, Jain NK (2003) Ultra
deformable liposomes: a recent tool for
78okffective transdermal drug delivery.
Indian J Pharm Sci 65:223–231
74. Barry B (2002) Transdermal drug delivery. In:
Aulton EM (ed) Pharmaceutics, the science of
dosage forms design, 2nd edn. Harcourt Publishers, Churchill Livingstone, Newyork, pp
499–433
75. Almira I, Blazek-welsh IA, Rhodes GD
(2001) Maltodextrin—
AAPS PharmSciTech 3:1–8
76. Biswal S, Murthy PN, Sahu J, Sahoo P, Amir F
(2008) Vesicles of non-ionic surfactants (Niosomes) and drug delivery potential. Int J
Pharm Sci Nanotech 1:1–8
77. Azmin MN, Florence AT, Handjani-Vila RM,
Stuart JF, Vanlerberghe G, Whittaker JS
(1985) The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption
and distribution of methotrexate in mice. J
Pharm Pharmacol 37:237–242
78. Manosroi A, Wongtrakul P, Manosroi J,
Sakai
H, Sugawara
Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf B Biointerfaces 30:129–
138
79. Balasubramaniam A, Kumar VA, Pillai KS
(2002) Formulation and in-vivo evaluation
of niosome encapsulated daunorubicin hydrochloride. Drug Dev Ind Pharm 28:1181–
1193
80. Ringsdorf H (1975) Structure and properties
of pharmacologically active polymers. J Polymer Sci Part C 51(1):135–153
81. Duncan R,
synthetic-polymers as potential drug carriers.
Adv Polym Sci 57:51–101
82. Duncan R, Lloyd JB, Kopecek J (1980) Degradation of side-chains of N-(2-hydroxypropyl) methacrylamide copolymers by lysosomal
Kopecek
based proniosomes.
F, Yuasa M et al (2003)
J (1984) Soluble

Polymer-Based Drug Delivery Systems: Design and Characterization 131
enzymes. Biochem Biophys Res Commun 94:
284–290
83. Khandare J, Minko T (2006) Polymer-drug
conjugates: progress in polymeric prodrugs.
Prog Polym Sci 31(4):359–397
84. Kopecek J, Kopeckova P, Minko T, Lu Z-R
(2000) HPMA copolymer-anticancer drug
conjugates: design, activity, and mechanism
of action. Eur J Pharm Biopharm 50(1):
61–81
85. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6(9):
688–701
86. Vogtle F, Richardt G, Werner N (2009)
Introduction. In: Vo¨gtle F, Richardt G, Werner N (eds) Dendrimer chemistry: concepts,
syntheses, properties, applications. Academic,
Wiley, pp 1–24
87. Buhleier E, Wehner W, Vo¨gtle F (1978)
“Cascade”- and “nonskid-chain-like” syntheses of molecular cavity topologies. Synthesis
9:155–158
88. Shi X, Majoros IJ, Baker JR (2005) Capillary
electrophoresis of poly(amidoamine) dendrimers: from simple derivatives to complex multifunctional medical nanodevices. Mol Pharm
2:278–294
89. Bosman AW, Janssen HM, Meijer EW (1999)
About dendrimers: structure, physical properties, and applications. Chem Rev 99:1665–
1688
90. Kolhe P, Khandare J, Pillai O, Kannan S, LiehLai M, Kannan RM (2006) Preparation, cellular transport, and activity of
polyamidoamine-based dendritic nanodevices
with a high drug payload. Biomaterials 27:
660–669
91. Menjoge AR, Kannan RM, Tomalia DA
(2010) Dendrimer-based drug and imaging
conjugates: design considerations for nanomedical applications. Drug Discov Today 15:
171–185
92. Tomalia DA (1991) Dendrimer research. Science 252:1231
93. Tomalia DA (2009) In quest of a systematic
framework for unifying and defining
nanoscience. J Nanopart Res 11:1251–1310
94. Tomalia DA (2012) Interview: an architectural journey: from trees, dendrons/dendrimers to nanomedicine. Interview by Hannah
Stanwix. Nanomedicine 7:953–956
95. Roberts MJ, Bentley MD, Harris JM (2002)
Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54(4):459–476
96. Abuchowski A, McCoy JR, Palczuk NC, van
Es T, Davis FF (1977) Effect of covalent
attachment of polyethyleneglycol on immunogenicity and circulating life of bovine liver
catalase. J Biol Chem 252(11):3582–3586
97. Duncan R, Gilbert HRP, Carbajo RJ, Vicent
MJ (2008) Polymer masked-unmasked protein therapy. 1. Bioresponsive dextrin-trypsin
and -melanocyte stimulating hormone conjugates designed for α- amylase activation. Biomacromolecules 9(4):1146–1154
98. Andreani T, Kiill CP, de Souza ALR, Fangueiro JF, Doktorovova´ S, Garcia ML, Gra-
˜
mia
o MPD, Silva AM, Souto EB (2015) E_ect
of cryoprotectants on the reconstitution of
silica nanoparticles produced by sol–gel technology. J Therm Anal Calorim 120:1001–
1007
99. Mathurin J, Pancani E, Deniset-Besseau A,
Kjoller K, Prater CB, Gref R, Dazzi A
(2018) How to unravel the chemical structure
and component localization of individual
drug-loaded polymeric nanoparticles by
using tapping AFM-IR. Analyst 143:5940–
5949
100. Mourdikoudis S, Pallares RM, Thanh NT
(2018) Characterization techniques for nanoparticles: comparison and complementarity
upon studying nanoparticle properties.
Nanoscale 10:12871–12934
101. Lu M, Yang X, Yang Y, Qin P, Wu X, Cai Z
(2017) Nanomaterials as assisted matrix of
laser desorption/ionization time-of-flight
mass spectrometry for the analysis of small
molecules. Nano 7:87
102. Yang Y, Jiang Y, Xu J, Yu J (2007) Conducting polymeric nanoparticles synthesized in
reverse micelles and their gas sensitivity
based on quartz crystal microbalance. Polymer 48:4459–4465
103. Dazon C, Witschger O, Bau S, Fierro V, Llewellyn PL (2019) Nanomaterial identification
of powders: comparing volume specific surface area, X-ray di_raction and scanning electron microscopy methods. Environ Sci Nano
6:152–162
104. Zielinska A,
Nowak I, Souto EB (2020) Loading, release
profile and accelerated stability assessment of
monoterpenes-loaded solid lipid nanoparticles (SLN). Pharm Dev Technol 25:1–13
Ferreira NR, Feliczak-Guzik A,


Chapter 7
Stimuli-Responsive Drug Delivery Systems: From Concept
to Clinical Translation
Manisha, Pritam Pal, Pradyut Das, and Vishwa Ranjan Upadhyay
Abstract
In order to address the shortcomings of traditional therapeutic modalities, this study offers a thorough
review of stimuli-responsive drug delivery systems (DDS) for programmed site-specific release that are
based on both endogenous and exogenous stimuli. This work focuses on the smart materials and mechanism of action of several stimuli-responsive polymeric carriers, which are important in both the extracellular
and intracellular domains of diseased tissues or cells. Research is being conducted globally to design new
stimuli-responsive carriers, both internal and external, for biotechnological applications in general and
biomedical and/or pharmaceutical applications in particular. This is because science has an ever-expanding
body of knowledge and awareness. An essential component of designing so-called smart DDS, which
sophisticatedly regulates dose loading, sustained release, individual variability, and ta rgeted permeability, is
the carriers’ dual-/multi-responsive, internal, and even external behaviors. Various stimulus-responsive
DDS have been developed, proposed, and utilized thus far. These include systems responsive to electrical,
magnetic, pH, temperature, photo/light-induced reactions, and redox stimuli. Additionally, dual and
multi-responsive DDS, which combine two or more of these stimuli, have been explored for enhanced
therapeutic efficiency. In order to close the research gap, a number of difficult issues still need to be resolved
despite the tremendous advancements made in the DDS field. To fill in the gaps in the literature, an attempt
has been made to draw attention to those important issues in this context. As a result, the focus was on the
mechanisms of drug release and the clinical applications of exogenous and endogenous stimuliresponsive DDS.
Key words Stimuli-responsive, Drug delivery, Polymeric carriers, Endogenous, Exogenous,
Nanotechnology
1 Introduction
The landscape of drug delivery systems has evolved significantly
over the past few decades. Traditional drug delivery methods, such
as oral and intravenous administration, have been the backbone of
therapeutic practices. While effective, these methods often present
challenges, including suboptimal bioavailability, systemic side
effects, and lack of targeted delivery [
driven the quest for more advanced drug delivery systems,
133
1]. These limitations have

134 Manisha et al.
culminating in the development of stimuli-responsive drug deliver y
systems (SRDDS). These systems are engineered to release therapeutic agents in response to specific physiological or external stimuli, offering a controlled, targeted, and efficient means of drug
delivery [
2].
2 Definition of Stimuli-Responsive Drug Delivery Systems
Stimuli-responsive drug delivery systems are advanced drug delivery platforms designed to release therapeutic agents in response to
specific internal or external triggers [
enhance therapeutic efficacy, minimize side effects, and provide
controlled and targeted delivery of drugs. The underlying concept
is to ensure that the drugs are released precisely where and when
they are needed, responding to specific physiological conditions or
external signals.
3]. These systems aim to
2.1 Types of Stimuli
Stimuli that trigger drug release in SRDDS can be broadly categorized into internal and external stimuli (Fig.
1).
1. Internal Stimuli
(a) pH: Variations in pH levels within different body environ-
ments (e.g., acidic pH in the stomach or tumor tissues)
(b) Temperature: Localized hyperthermia in inflamed or
cancerous tissues
(c) Redox potential: Differences in oxidative and reductive
conditions inside and outside cells
(d) Enzymatic activity:
Presence
of specific enzymes at
disease sites
Fig. 1 Classification of various types of stimuli

Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation 135
2. External Stimuli
(e) Light: Controlled exposure to specific wavelengths of light
(f) Magnetic Fields: Application of external magnetic fields
(g) Electric Fields: Application of electric currents or fields
3 Mechanism of Stimuli Responsiveness
The mechanisms by which SRDDS respond to stimuli involve
various physical, chemical, and biological processes that trigger
drug release. Understanding these mechanisms is crucial for
designing effective stimuli-responsive systems.
3.1 pH-Responsive Systems
Mechanism: These systems utilize materials that undergo changes
in solubility, charge, or structure in response to pH variations
(Fig. 2). For example, polymers containing acidic or basic
groups can swell, dissolve, or degrade at specific pH levels,
releasing the encapsulated drug.
Example: Poly(methacrylic acid) nanoparticles that release drugs in
acidic tumor microenvironments.
Fig. 2 Mechanism of action of pH-responsive drug delivery system

136 Manisha et al.
Fig. 3 Mechanism of action of temperature-responsive drug delivery system
3.2 TemperatureResponsive Systems
3.3 LightResponsive Systems
3.4 RedoxResponsive Systems
3.5 MagneticResponsive Systems
Mechanism: These systems are based on materials that exhibit phase
transitions at certain temperatures (Fig.
3). Thermo-responsive
polymers, such as poly(N-isopropylacrylamide), can change
from a hydrophilic to a hydrophobic state at a critical temperature, causing drug release.
Example: Injectable hydrogels that solidify at body temperature,
allowing localized drug delivery.
Mechanism: Light-responsive systems use photo-responsive mate-
rials that undergo structural changes upon exposure to specific
wavelengths of light. This can include photoisomerization,
photodegradation, or photothermal effects.
Example: Gold nanoparticles that convert light energy into heat,
triggering drug release.
Mechanism: Redox-responsive systems often utilize disulfide lin-
kages or other redox-responsive bonds that are stable under
extracellular oxidative conditions but cleaved in the reductive
intracellular environment, leading to drug release (Fig.
4).
Example: Micelles with disulfide cross-linked cores that degrade in
the presence of intracellular glutathione.
Mechanism: These systems incorporate magnetic nanoparticles that
can be directed and heated by an external magnetic field,
causing drug release through thermal or mechanical means.
Example: Magnetic liposomes that release drugs upon exposure to
an alternating magnetic field.
3.6 ElectricResponsive Systems
3.7 EnzymeResponsive Systems
Mechanism: These systems use materials that undergo electro-
chemical reactions or changes in conductivity upon exposure
to electric fields, enabling controlled drug release.
Example: Conductive polymers that release drugs in response to
applied electrical stimuli.
Mechanism: These systems are designed with substrates that are
specifically cleaved by enzymes present at disease sites. The
enzymatic action breaks down the carrier matrix or releases
the drug from its conjugate.
Example: Polymeric nanoparticles containing peptide sequences
cleavable by matrix metalloproteinases (MMPs) overexpressed
in tumors.

Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation 137
4 Materials
4.1 pH-Responsive Materials
Fig. 4 Mechanism of action of redox-responsive drug delivery system
The phenomena that affect an activity at a specific location or target
tissue to bring about beneficial activities for the drug release via a
variety of mechanisms is included in the stimuli-responsive drug
delivery system. These materials are referred to as “environmentally
responsive materials” or “stimuli-responsive materials” [
5 for a visualization of different types of materials.
Fig.
4, 5]. See
It is necessary for a pH-responsive drug delivery system (DDS) to
protect the drug capsule while it is in the bloodstream
(pH 7.3–7.4) and to release the drug or trigger particular actions
(like cell-penetrating ability) when the tumor interstitial space
(pH 6.8–7.2) or intracellular compartments (pH 4.5–5.5), endosomes (pH 5–6), and cytoplasm (pH slightly above pH 7.0) are
reached [115–117]. Paclitaxel (PTX) and antagomir-10b were
developed to be delivered via a pH-responsive antimicrobial
peptide-mediated liposomal delivery system in mice with metastatic

138 Manisha et al.
Fig. 5 Classification of various types of materials
mammary tumor models. Antagomirs are single-stranded RNA
analogues that have undergone chemical modification and have
been conjugated with cholesterol. This increases their stability
and function by hybridizing with mature miRNA and inhibiting
its activity [
6]. One well-known cytotoxic drug is paclitaxel. The
researchers attached [D]-H6L9, a previously reported
pH-dependent antimicrobial peptide to the liposome surface
7
[
]. pH-responsive materials can be developed using materials
with ionizable groups, and
non-conventional techniques. When metformin hydrochloride
(MH) was added to mesoporous bioglass (MBG) as a model
drug, it effectively functions as a pH-responsive carrier. Afterward,
hydroxyapatite (HAp) was added to the MBG pores at different
concentrations and times to regulate the release of MH. Following
drug loading and HAp mineralization
volume, and surface
decreased by longer mineralization durations and higher ion concentrations, suggesting that prolonged mineralization and higher
ion concentrations improve HAp mineralization Drug-loading efficiency stayed unchanged despite the breakdown of HAp in acidic
conditions, which changed the MH release profile based on mineralization time and ion concentration. These observat
that this pH-responsive material
tic agents targeting tumors and inflammatory sites [
ples of materials that
these materials can be made using
, a decrease in pore size,
area was observed. Pore size was also further
ions suggest
is a promising car rier for therapeu-
8]. Key exam-
respond to pH are provided in Table
1.
hermo-
4.2 T
Responsive Materials
Thermo-responsive materials exhibit changes in their physical
properties or conformations in response to temperature variations.
These materials are utilized in various biomedical applications, such
as tissue engineering and drug delivery. However, the balance
between hydrophilic and hydrophobic properties, as well as the
Соседние файлы в папке Библиотека им академика М.И. Перельмана
